Claudia E. Paba‐Prada
About
In The Last Decade
Claudia E. Paba‐Prada
27 papers receiving 648 citations
Peers
Comparison fields: 5 of 48
- Hematology 470
- Molecular Biology 462
- Oncology 305
- Genetics 146
- Pathology and Forensic Medicine 100
Countries citing papers authored by Claudia E. Paba‐Prada
This map shows the geographic impact of Claudia E. Paba‐Prada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia E. Paba‐Prada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia E. Paba‐Prada more than expected).
Fields of papers citing papers by Claudia E. Paba‐Prada
This network shows the impact of papers produced by Claudia E. Paba‐Prada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia E. Paba‐Prada. The network helps show where Claudia E. Paba‐Prada may publish in the future.
Co-authorship network of co-authors of Claudia E. Paba‐Prada
This figure shows the co-authorship network connecting the top 25 collaborators of Claudia E. Paba‐Prada. A scholar is included among the top collaborators of Claudia E. Paba‐Prada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia E. Paba‐Prada. Claudia E. Paba‐Prada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 62 | |
| 2 | 73 | |
| 3 | 15 | |
| 4 | 20 | |
| 5 | 15 | |
| 6 | 1 | |
| 7 | 5 | |
| 8 | 8 | |
| 9 | 8 | |
| 10 | 60 | |
| 11 | 3 | |
| 12 | 58 | |
| 13 | 3 | |
| 14 | 3 | |
| 15 | 11 | |
| 16 | An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma | 1 |
| 17 | 79 | |
| 18 | 9 | |
| 19 | IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. | 3 |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.